Interesting statement in the conclusion made, I know we have talked about this being the case, but to see it in the article is good to see.
"None of the products from different manufactures analyzed fulfills any characteristics or requirements to be classified as a generic product of another manufacture, but each of which presents a new medical entity in a regulatory sense unless its similarity can be convincingly demonstrated by further investigations."
Interesting statement in the conclusion made, I know we have...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 25.0¢ | $36.40K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40816 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 44646 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |